Craig Tendler - 22 Aug 2026 Form 4 Insider Report for Parabilis Medicines, Inc. (PBLS)

Reporting relationship: Director
Issuer ticker: PBLS
Reported as of: 22 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Aug 2026, 18:14:33 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Teresa Jurgensen, Attorney-in-Fact

Key filing fact

Craig Tendler filed Form 4 for Parabilis Medicines, Inc. (PBLS) on 25 Aug 2026.

Key facts

This page summarizes Craig Tendler's Form 4 filing for Parabilis Medicines, Inc. (PBLS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2026, 18:14.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002061924 Primary reporting owner

Tendler Craig

Relationship: Director
Address: C/O PARABILIS MEDICINES, INC., 30 ACORN PARK DRIVE, 6TH FLOOR, CAMBRIDGE
Signature: /s/ Teresa Jurgensen, Attorney-in-Fact
Signature date: 25 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PBLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +20,294
Change %
Price: $0.000000^*
Shares after: 20,294
Date: 22 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,294
Exercise price: $39.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date.